What Alcon PanOptix is
AcrySof IQ PanOptix is a diffractive trifocal IOL from Alcon Laboratories, approved by the FDA on August 26, 2019 under PMA P040020, supplement S087. The primary clinical model is the non-toric TFNT00; toric versions (TFNT30/40/50/60, for 1.50–3.75 D of corneal astigmatism) share the same optical platform but were not part of the clinical arm reported in this SSED. As a true trifocal, PanOptix uses diffractive rings to create three distinct focal points — distance, intermediate, and near — rather than the continuous extended range used by EDOF-style lenses.
What it looks like
The image below is reproduced from the lens's own FDA regulatory filing, not manufacturer marketing artwork, so what is shown is exactly what the FDA reviewed and approved.
Source: FDA SSED, PMA P040020/S087, Figure 1
Where the data on this page comes from
Every figure below comes from PanOptix's FDA Summary of Safety and Effectiveness Data (SSED) — the public document FDA published alongside approval, based on the pivotal trial Alcon submitted (PMA P040020/S087: 250 enrolled, 243 implanted, 12 U.S. sites, non-randomized, vision-assessor-masked, 6-month follow-up; 127 PanOptix and 113 monofocal-control first eyes analyzed for the acuity results below). Every number is cited to its table so you can check it directly.
One structural note: the SSED's numeric acuity, satisfaction, and disturbance tables are used below because they're published as text. Contrast sensitivity, by contrast, is presented only as graphs in this document (Figures 5–8) — where that's the case, we summarize the SSED's own stated conclusion rather than estimating exact numbers we can't verify from a chart image.
Visual acuity by distance
Bars show relative acuity — longer bar = sharper vision. Exact logMAR value (lower is better) and Snellen equivalent shown at right.
Source: FDA SSED, PMA P040020/S087, Table 23
This is the classic trifocal pattern: distance vision essentially matches the monofocal control, while both intermediate and near vision show a large, consistent advantage — reflecting the lens's three dedicated focal points. The trial's pre-specified statistical targets (non-inferiority for distance, superiority for near and intermediate) were each met, per the SSED's own conclusion (p.37–38).
Contrast sensitivity — what the graphs show
The SSED's own stated conclusion, drawn from binocular contrast-sensitivity figures at both photopic (bright) and mesopic (low-light) conditions with and without glare (Figures 5–8, pp.30–33), is: "The binocular contrast sensitivity results were slightly reduced for the PanOptix IOL compared to the monofocal control IOL, however these differences were not clinically meaningful." No numeric per-spatial-frequency table accompanies this conclusion in the SSED, so we're reporting the document's own summary rather than reconstructing values from a chart image.
Patient satisfaction (IOLSAT questionnaire)
% of patients, IOL Satisfaction Questionnaire (IOLSAT).
Source: FDA SSED, PMA P040020/S087, Table 22
The SSED also states that spectacle independence (the share of patients answering "Never" to needing glasses) showed a statistically significant 71.2 percentage-point difference favoring PanOptix — a striking figure, though the underlying per-group percentages weren't available in the pages of the document we could access, so we're citing the reported difference rather than the two absolute numbers.
Visual disturbances (halos, glare, starbursts)
% of patients reporting at least "a little" bother (i.e., not "not bothered at all").
Source: FDA SSED, PMA P040020/S087, Table 20
These figures represent any degree of bother, from mild to severe, which is why the percentages look higher than the "spontaneous report" style figures we cite for some other lenses — it's a directed question rather than an unprompted mention. On the higher end of that same scale ("quite a bit" or "very much" bothered), the gap narrows but doesn't close: 11.1% of PanOptix patients versus 1.8% of control patients for halos, and 12.0% versus 1.8% for starbursts, with glare closer between groups (8.7% vs. 7.2%).
Possible limitations, based on this data
- Halos, glare, and starbursts were reported at meaningfully higher rates than with the monofocal control lens across every severity level measured, including the "quite a bit / very much bothered" tier (up to 12.0% of PanOptix patients vs. up to 1.8% of control patients).
- Contrast sensitivity was slightly reduced versus the monofocal control; the SSED describes this as not clinically meaningful, but the underlying figures exist only as graphs, not a published numeric table.
- The clinical trial evaluated only the non-toric TFNT00 model — the toric versions (TFNT30/40/50/60) share the optical platform but were not separately tested in this pivotal study.
- This is one 6-month industry-sponsored registration trial (127 PanOptix eyes vs. 113 control) — a valid basis for FDA approval, but shorter and smaller than the accumulated real-world literature on this widely used lens.
- As with any diffractive multifocal/trifocal design, some patients need an adaptation period, and results depend heavily on precise biometry and a healthy retina and ocular surface.
Who this lens may suit
This dataset is consistent with PanOptix's general reputation: strong, well-documented gains at intermediate and near distance and high patient-reported satisfaction, alongside a meaningfully higher (though mostly mild-to-moderate) rate of halos, glare, and starbursts than a monofocal lens. Patients who prioritize spectacle independence across all three distances and are less bothered by nighttime visual phenomena are more likely to be good candidates than patients who drive frequently at night or who are highly sensitive to glare. This is, as always, a decision for your surgeon based on your own eye measurements, pupil behavior, and lifestyle.
How it compares
PanOptix is a trifocal lens within the broader full-range category — using three discrete diffractive focal points rather than a continuous extended range. For the category-level trade-offs against non-diffractive EDOF and enhanced monofocal designs, see Full Range / Trifocal / Multifocal. For a broader look at why some patients in this general lens category report dissatisfaction, see Why Do Some Presbyopia-Correcting IOL Patients Report Dissatisfaction?
A note on how manufacturers present this same data
Materials built from this same trial for sales and marketing purposes commonly lead with the satisfaction and spectacle-independence figures shown above — which are genuine and strong — while presenting visual-disturbance data, if shown at all, less prominently, using different comparator products, or via bench-optics metrics rather than the patient-reported outcomes shown side-by-side here. Much of this material draws on internal "Data on File" studies that aren't independently published, and is frequently restricted to healthcare-professional distribution rather than intended for patients to read directly. We've used the public FDA record and shown the favorable and unfavorable results from the same trial together, because both halves matter to a patient weighing this decision.
A note on this review
This page is educational content, not a clinical trial result and not a personal recommendation. Every figure is sourced directly from the FDA's public SSED for PMA P040020/S087 and cited by table number so you can verify it yourself; where the source document presents a result only as a graph, we've said so rather than estimating numbers we can't confirm. Actual outcomes vary from patient to patient, and the right lens for you can only be determined by a qualified ophthalmic surgeon based on your individual eye measurements and health history.